EPISODE · May 6, 2021 · 29 MIN
A Diagnostics Company Moves to Developing Precision Cancer Therapies
from The Bio Report · host Levine Media Group
Earlier this year NovelluxDx rebranded itself as Fore Biotherapeutics signaling a shift from being a diagnostics company to its new life as a precision cancer therapeutics drug developer. Building on its functional genomics platform, the company is in-licensing small molecule drug candidates it sees having potential to treat hyper-targeted patient populations. We spoke to Usama Malik, CEO of Fore Biotherapeutics, about the move from diagnostics to drug development, the approach Fore is taking, and why it thinks it can see value in molecules that others may miss.
What this episode covers
Earlier this year NovelluxDx rebranded itself as Fore Biotherapeutics signaling a shift from being a diagnostics company to its new life as a precision cancer therapeutics drug developer. Building on its functional genomics platform, the company is in-licensing small molecule drug candidates it sees having potential to treat hyper-targeted patient populations. We spoke to Usama Malik, CEO of Fore Biotherapeutics, about the move from diagnostics to drug development, the approach Fore is taking, and why it thinks it can see value in molecules that others may miss.
NOW PLAYING
A Diagnostics Company Moves to Developing Precision Cancer Therapies
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m